Description: Renalytix Plc develops artificial intelligence-enabled in vitro diagnostic solutions for clinical management kidney diseases in the United States. The company offers KidneyIntelX, a diagnostic platform that employs an artificial intelligence-enabled algorithm that combines various data inputs, including validated blood-based biomarkers, inherited genetics, and personalized patient data from electronic health record systems to generate a unique patient risk score. Its products are used in kidney disease diagnosis and prognosis, clinical care, patient stratification for drug clinical trials, and drug target discovery. It has a license agreement with Mount Sinai Health System to develop and commercialize licensed products in connection with the application of artificial intelligence for the diagnosis of kidney disease; and partnership agreement with Atrium Health, Wake Forest Baptist Health, and Wake Forest School of Medicine to implement an advanced clinical care model to improve kidney health and reduce kidney disease progression and kidney failure. The company was formerly known as Renalytix AI plc and changed its name to Renalytix Plc in June 2021. The company was incorporated in 2018 and is based in New York, New York.
Home Page: renalytix.com
1460 Broadway
New York,
NY
10036
United States
Phone:
646 397 3970
Officers
| Name | Title |
|---|---|
| Mr. James R. McCullough M.B.A. | CEO & Director |
| Mr. Fergus Fleming | CTO & Executive Director |
| Dr. Michael J. Donovan M.D., Ph.D. | Chief Medical Officer |
| Mr. Julian Huw Baines M.B.E. | Executive Chairman |
| Mr. Howard B. Doran Jr. | President |
| Mr. Joel R. Jung MBA | Chief Financial Officer |
| Mr. Salim Gulamabbas Hamir F.C.A. | Company Secretary |
Exchange: OTCQB
Country: US : United States of America
Currency: US Dollar ($)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 0 |
| Price-to-Sales TTM: | 0 |
| IPO Date: | |
| Fiscal Year End: | June |
| Full Time Employees: | 0 |